Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer

被引:40
|
作者
Kritsch, Daniel [1 ]
Hoffmann, Franziska [1 ,8 ]
Steinbach, Daniel [1 ,9 ]
Jansen, Lars [1 ]
Photini, Stella Mary [2 ]
Gajda, Mieczyslaw [3 ]
Mosig, Alexander S. [4 ]
Sonnemann, Juergen [5 ]
Peters, Sven [6 ]
Melnikova, Margarita [7 ]
Thomale, Juergen [7 ]
Duerst, Matthias [1 ]
Runnebaum, Ingo B. [1 ]
Haefner, Norman [1 ]
机构
[1] Friedrich Schiller Univ, Jena Univ Hosp, Dept Gynecol & Reprod Med, Klinikum 1, D-07747 Jena, Germany
[2] Friedrich Schiller Univ, Jena Univ Hosp, Dept Obstet, Jena, Germany
[3] Friedrich Schiller Univ, Jena Univ Hosp, Inst Pathol, Jena, Germany
[4] Friedrich Schiller Univ, Jena Univ Hosp, Dept Biochem 2, Jena, Germany
[5] Friedrich Schiller Univ, Jena Univ Hosp, Dept Pediat Hematol & Oncol, Childrens Clin, Jena, Germany
[6] Friedrich Schiller Univ, Jena Univ Hosp, Expt Ophthalmol, Jena, Germany
[7] Univ Hosp Duisburg Essen, Inst Cell Biol, DNA Repair Lab, Essen, Germany
[8] Friedrich Schiller Univ, Jena Univ Hosp, Dept Otolaryngol, Jena, Germany
[9] Friedrich Schiller Univ, Jena Univ Hosp, Dept Urol, Jena, Germany
关键词
platin resistance; DNA damage response; ovarian cancer; prognosis; NUCLEOTIDE EXCISION-REPAIR; MITOTIC CATASTROPHE; ANTICANCER DRUGS; CELLS; RESISTANCE; CHEMOTHERAPY; MECHANISMS; APOPTOSIS; PROTEIN; TRIB2;
D O I
10.1002/ijc.30860
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim was to identify methylated genes with functional involvement in cisplatin-resistance development of epithelial ovarian cancer (EOC). Genome-wide analyses of hypermethylated CpG-islands in resistant cell lines in combination with qRT-PCR analyses were used to identify epigenetically silenced genes. EOC-Type-II tumors were analyzed for gene methylation and expression and TCGA data were interrogated in-silico. Experiments revealed 37 commonly hypermethylated genes in resistant cells of which Tribbles 2 (TRIB2) showed the most pronounced downregulation on mRNA level and was characterized further. TRIB2 showed a reactivation after 5'-Aza-Cytidine treatment in resistant cells but a cisplatin-dependent, prominent upregulation on mRNA level in sensitive cells, only. Re-expression in resistant A2780 cells increased the sensitivity to cisplatin and other DNA-damaging agents, but not taxanes. Contrary, knockdown of TRIB2 increased resistance to cisplatin in sensitive cells. TRIB2 was involved in the induction of a cisplatin-dependent cell cycle arrest and apoptosis by influencing p21 and survivin expression. An increased Pt-DNA-adduct formation in TRIB2 re-expressing cells did not translate in higher levels of dsDNA damage (yH2AX-foci). Thus, TRIB2 is potentially involved in the signal transduction from nucleotide excision repair of intra-strand cross links. Importantly, patient stratification of two homogenous cohorts of EOC-Type-II patients from Jena (n=38) and the TCGA (n=149) by TRIB2 mRNA expression consistently revealed a significantly decreased PFS for patients with low TRIB2 levels (log-rank p < 0.05). Tumors from resistant patients expressed the lowest levels of TRIB2. Downregulation of TRIB2 contributes to platin-resistance and TRIB2 expression should be validated as prognostic and predictive marker for EOC.
引用
收藏
页码:1600 / 1613
页数:14
相关论文
共 50 条
  • [1] Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer
    Kritsch, D.
    Hoffmann, F.
    Thomale, J.
    Duerst, M.
    Runnebaum, I. B.
    Haefner, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 176 - 177
  • [2] Attenuation of DNA damage response by hyperthermic cisplatin in epithelial ovarian cancer
    Horowitz, M. P.
    Esakov, E. L.
    Kpegba, C. S.
    Braley, C.
    Michener, C. M.
    Rose, P. G.
    DeBernardo, R.
    Reizes, O.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 151 - 152
  • [3] Characterization of Tribbles 1 in Epithelial Ovarian Cancer
    Bauerschmitz, Leonard
    Raddatz, Vanessa
    Duerst, Matthias
    Runnebaum, Ingo B.
    Haefner, Norman
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 94 - 94
  • [4] MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells
    Zhao, Hong-Min
    Wei, Wei
    Sun, Yu-Hui
    Gao, Jian-Hua
    Wang, Qi
    Zheng, Jian-Hua
    TUMOR BIOLOGY, 2015, 36 (09) : 6867 - 6873
  • [5] The predictive and prognostic roles of DNA damage response genes in epithelial ovarian cancer
    Alkema, Nicolette G.
    Everts, Marieke
    van der Zee, Ate G. J.
    ten Hoor, Klaske A.
    Hollema, Harry
    de Jong, Steven
    van Vugt, Marcel A. T. M.
    Wisman, Bea G. B. A.
    CANCER RESEARCH, 2012, 72
  • [6] KLF4 activates LATS2 to promote cisplatin sensitivity in ovarian cancer through DNA damage
    Ma, Ling
    Zhao, Xiaoting
    Lu, Xiang
    Shen, Jiahui
    Huang, Jiankang
    ANTI-CANCER DRUGS, 2025, 36 (01) : 49 - 61
  • [7] Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer
    Guo, Jianfeng
    Zhu, Yapei
    Yu, Lili
    Li, Yuan
    Guo, Jing
    Cai, Jing
    Liu, Lin
    Wang, Zehua
    PEERJ, 2021, 9
  • [8] ADAM9 mediates Cisplatin resistance in gastric cancer cells through DNA damage response pathway
    Zhang, Xiao-yu
    Zhao, Chan-yuan
    Dong, Jia-ming
    Du, Cun-pu
    Zhang, Chen-li
    Yang, Ai-jun
    Zhou, Quan
    Liu, Wei
    Dang, Yun
    Shang, Li-na
    Zhou, Yong-ning
    Wang, Yu-ping
    Wang, Chen-yu
    Wang, Min
    Li, Min
    MEDICAL ONCOLOGY, 2025, 42 (04)
  • [9] The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer
    Sellar, GC
    Watt, KP
    Li, L
    Nelkin, BD
    Rabiasz, GJ
    Porteous, DJ
    Smyth, JF
    Gabra, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2002, 21 (05) : 929 - 933
  • [10] Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin
    Gaponova, Anna V.
    Deneka, Alexander Y.
    Beck, Tim N.
    Liu, Hanqing
    Andrianov, Gregory
    Nikonova, Anna S.
    Nicolas, Emmanuelle
    Einarson, Margret B.
    Golemis, Erica A.
    Serebriiskii, Ilya G.
    ONCOTARGET, 2017, 8 (12) : 19156 - 19171